Both total daily doses and all dosing frequencies of olodaterol tested provided highly significant improvements versus placebo in efficacy variables based on pulmonary function tests, albeit with different 24-h bronchodilatory profiles.
← all excerpts
Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.
1
—
—